Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04580797 · ClinicalTrials.gov registry record · Phase 1
Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT04580797 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 36 participants.
The verdict
NCT04580797, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of PF-06700841 following single and multiple oral doses as modified release (MR) formulations in healthy, adult participants under fasted and fed conditions. The objective of Part A is to evaluate the relative bioavailability and food effect of 2 new MR formulations, MR1 and MR2. The objective of Part B is to evaluate the PK and safety/tolerability of MR3 formulation following multiple dose administration over a 7-day period. Overall, results from both parts will facilitate further development of an MR formulation for future clinical studies.
Interventions
- OTHER Placebo
- DRUG PF-06700841 IR
- DRUG PF-06700841 MR1
- DRUG PF-06700841 MR2
- DRUG PF-06700841 MR3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2021-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04580797
The ClinicalTrials.gov registry entry for NCT04580797 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04580797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04580797 about?
NCT04580797 is a clinical study titled "Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations". The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of PF-06700841 following single and multiple oral doses as modified release (MR) formulations in healthy, adult participants under fasted and fed conditions. The objective of Part A is to evaluate the relativ...
What is the current status of trial NCT04580797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2020-10-02. Estimated completion is 2021-01-11.
What interventions are being tested in trial NCT04580797?
The interventions under investigation include: Placebo (OTHER), PF-06700841 IR (DRUG), PF-06700841 MR1 (DRUG), PF-06700841 MR2 (DRUG), PF-06700841 MR3 (DRUG).
Who is sponsoring clinical trial NCT04580797?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.